3,4-dibutoxy-benzoyl chloride | 134766-03-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4-dibutoxy-benzoyl chloride
• 英文别名: 3,4-Dibutoxybenzoyl chloride；3,4-dibutoxybenzoyl chloride
• CAS: 134766-03-3
• 化学式: C₁₅H₂₁ClO₃
• 分子量: 284.783
• InChiKey: DYSIGNBBVKLWHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  19
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,4-dibutoxy-benzoyl chloride 在 三氯氧磷 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 为溶剂， 反应 42.0h， 生成 2-(3,4-bis(butoxy)phenyl)-5-(pyridine-4-yl)-1,3,4-oxadiazole
  参考文献：
  名称：

  Organogels from unsymmetrical π-conjugated 1,3,4-oxadiazole derivatives

  摘要：

  在这项研究中，我们合成并筛选了非对称Β-共轭凝胶剂2-(3,4-双(烷氧基)苯基)-5-(吡啶-4-基)-1,3,4-恶二唑[4-POXD-Bn (n = 4, 8, 12)]在各种溶剂中的凝胶化性能。4-POXD-B8凝胶的临界凝胶浓度(CGC)和凝胶-溶液相变温度(Tgel)的趋势以及凝胶剂端链长度与凝胶化能力之间的关系表明，疏溶剂效应在凝胶化过程中起着关键作用。对于我们所研究的特定凝胶剂，我们观察到疏溶剂力的强度与溶剂性质有关。我们使用溶剂极性参数：极性溶解度参数(Δa)、介电常数(µ)和极性参数(ET(30))对溶剂对凝胶化的影响进行了定量研究。结果表明，4-POXD-B8凝胶化的有利Δa域和ET(30)域分别在8.1-12.6 (cal cm-3)1/2和43.3-55.7 kcal mol-1的范围内。同时，溶剂中Δa和ET(30)的降低不利于凝胶化。此外，我们通过扫描电子显微镜(SEM)研究了溶剂对凝胶微观结构的影响。SEM图像显示，4-

  DOI：

  10.1039/c3nj40648b
• 作为产物：
  描述：

  3,4-dibutoxy-benzoic acid 在 氯化亚砜 作用下， 反应 8.0h， 生成 3,4-dibutoxy-benzoyl chloride
  参考文献：
  名称：

  Organogels from unsymmetrical π-conjugated 1,3,4-oxadiazole derivatives

  摘要：

  在这项研究中，我们合成并筛选了非对称Β-共轭凝胶剂2-(3,4-双(烷氧基)苯基)-5-(吡啶-4-基)-1,3,4-恶二唑[4-POXD-Bn (n = 4, 8, 12)]在各种溶剂中的凝胶化性能。4-POXD-B8凝胶的临界凝胶浓度(CGC)和凝胶-溶液相变温度(Tgel)的趋势以及凝胶剂端链长度与凝胶化能力之间的关系表明，疏溶剂效应在凝胶化过程中起着关键作用。对于我们所研究的特定凝胶剂，我们观察到疏溶剂力的强度与溶剂性质有关。我们使用溶剂极性参数：极性溶解度参数(Δa)、介电常数(µ)和极性参数(ET(30))对溶剂对凝胶化的影响进行了定量研究。结果表明，4-POXD-B8凝胶化的有利Δa域和ET(30)域分别在8.1-12.6 (cal cm-3)1/2和43.3-55.7 kcal mol-1的范围内。同时，溶剂中Δa和ET(30)的降低不利于凝胶化。此外，我们通过扫描电子显微镜(SEM)研究了溶剂对凝胶微观结构的影响。SEM图像显示，4-

  DOI：

  10.1039/c3nj40648b

文献信息

• Tailoring thermotropic cubic mesophases: amphiphilic polyhydroxy derivatives
  作者：Konstanze Borisch、Siegmar Diele、Petra Göring、Horst Kresse、Carsten Tschierske

  DOI：10.1039/a705359b

  日期：——

  Novel amphiphilic polyhydroxy compounds [N-(3,4-dialkoxybenzoyl)-1-amino-1-deoxy-d-glucitols (glucamides), N-(3,4-dialkoxybenzoyl)-1-deoxy-1-methylamino-d-glucitols, N-(3,4,5-trialkoxybenzoyl)-1-deoxy-1-methylamino-d-glucitols (N-methylgucamides), 1-benzoylaminopropane-2,3-diols, 2-benzoylaminopropane-1,3-diols, 2-(3,4,5-tridodecyloxybenzoylamino)-2-(hydroxymethyl)propane-1,3-diol and (3,4,5-tridodecyloxybenzoyl)bis(2,3-dihydroxypropyl)amine] have been synthesized. Their thermotropic liquid crystalline phases were investigated by means of polarizing microscopy, differential scanning calorimetry and X-ray diffraction. Depending on the chain length, and the size of the hydrophilic polyhydroxy units, different mesophases have been found: smectic A phases (SA), inverted bicontinuous cubic phases (CubV2 , Ia3d), hexagonal columnar phases (ColH2) and micellar cubic mesophases (CubI2 , Pn3m or P43n). In strong analogy to lyotropic systems, the type of thermotropic mesophase depends on the ratio between the volume of the lipophilic moiety and the surface area of the hydrophilic moiety at the hydrophilic–lipophilic interface. The crossing from zero interface curvature (SA phase) to the finite negative curvature of the inverted cylindrical aggregates of the columnar mesophase takes place via bicontinuous cubic mesophases. The cylindrical aggregates of the columnar mesophase are stable over a rather broad range of variation of the structural parameter. At a certain degree of the size of the lipophilic moiety in respect to the surface area of the hydrophilic group, however, the transition from the hexagonal columnar to a micellar cubic mesophase takes place. On the basis of proton conductivity measurements and from packing considerations we propose that this cubic lattice is built up by eight closed micelles per unit cell which have a rod-like shape and represent small segments of extended columns. Therefrom we can propose a model for the transformations between these different thermotropic mesophases.

  新型两亲聚羟基化合物[N-(3,4-二烷氧基苯甲酰)-1-氨基-1-脱氧-d-葡萄糖醇（葡萄糖酰胺）、N-(3,4-二烷氧基苯甲酰)-1-脱氧-1-甲基氨基-d-葡萄糖醇、N-(3,4,5-三烷氧基苯甲酰)-1-脱氧-1-甲基氨基-d-葡萄糖醇（N-甲基葡萄糖酰胺）、1-苯甲酰氨基-丙烷-2,3-二醇、2-苯甲酰氨基-丙烷-1,3-二醇、2-(3,4,5-三十二烷氧基苯甲酰氨基)-2-(羟甲基)丙烷-1,3-二醇以及(3,4,5-三十二烷氧基苯甲酰)双(2,3-二羟基丙基)胺]已被合成。通过偏光显微镜、差示扫描量热法和X射线衍射法研究了它们的热致液晶相。根据链长和亲水性聚羟基单元的大小，发现了不同的介相：斜方相（SA）、倒置双连续立方相（CubV2，Ia3d）、六角柱相（ColH2）和胶束立方介相（CubI2，Pn3m或P43n）。与液晶系统非常相似，热致介相的类型取决于亲脂部分的体积与亲水部分在亲水-亲脂界面的表面积之间的比率。从零界面曲率（SA相）到柱状介相的有限负曲率倒置圆柱聚集体的过渡，通过双连续立方介相进行。柱状介相的圆柱聚集体在结构参数变化的较宽范围内是稳定的。然而，在亲脂部分与亲水基团表面积的某个比率下，发生从六角柱相到胶束立方介相的转变。根据质子导电性测量和包装考虑，我们提出该立方格子由每个单元格的八个闭合胶束构成，这些胶束呈杆状，代表扩展柱的小段。由此，我们可以提出一个不同热致介相之间转变的模型。
• Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis
  申请人：Snow D. Alan

  公开号：US20070225362A1

  公开（公告）日：2007-09-27

  Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed in systemic AA amyloidosis and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

  双羟基和三羟基芳基化合物及其甲氧基二氧杂环化物和药学上可接受的酯类，它们的合成，含有它们的制药组合物，以及它们在治疗淀粉样疾病，特别是阿尔茨海默病中观察到的Aβ淀粉样变性，IAPP淀粉样变性，例如在2型糖尿病中观察到的AA / SAA淀粉样变性，以及突触蛋白病，例如在帕金森病中观察到的应用，以及用于制造这种治疗药物。
• Compounds, compositions and methods for the treatment of synucleinopathies
  申请人：Esposito Luke

  公开号：US20070276034A1

  公开（公告）日：2007-11-29

  Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as Parkinson's disease, and the manufacture of medicaments for such treatment.

  双-和三-二羟基芳基化合物及其亚甲二氧基类似物和药学上可接受的酯，它们的合成，含有它们的制药组合物，以及它们在治疗突触核病，如帕金森病中的应用和制造用于这种治疗的药物。
• COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE
  申请人：Snow Alan D.

  公开号：US20090069432A1

  公开（公告）日：2009-03-12

  Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

  双-和三-二羟基芳基化合物及其二氧化甲基类似物和药学上可接受的酯，它们的合成，含有它们的制药组合物，以及它们在治疗淀粉样疾病中的应用，尤其是Aβ淀粉样蛋白病，如阿尔茨海默病，IAPP淀粉样蛋白病，如2型糖尿病，以及突触核病，如帕金森病，和用于制造这种治疗药物。
• Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease
  申请人：SNOW Alan D.

  公开号：US20110172239A1

  公开（公告）日：2011-07-14

  Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

  双-和三-二羟基芳基化合物及其亚甲二氧基类似物和药学上可接受的酯，它们的合成，含有它们的制药组合物，以及它们在治疗淀粉样疾病，特别是阿尔茨海默病中观察到的Aβ淀粉样蛋白病，IAPP淀粉样蛋白病，如在2型糖尿病中观察到的和突触核蛋白病，如在帕金森病中观察到的用途，以及制造此类治疗药物。